Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia
- Tibor J. Kovacsovics,
- Alice Mims,
- Mohamed E. Salama,
- Jeremy Mark Pantin,
- Narayanam Rao,
- Ken M. Kosak
- University of Utah,
- Medical University of South Carolina,
- ,
- Porta Clinica PLLC,
- University of Georgia,
- Wake Forest University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>Relapses in acute myelogenous leukemia (AML) are a result of quiescent leukemic stem cells (LSCs) in marrow stromal niches, where they resist chemotherapy. LSCs employ CXCL12/CXCR4 to home toward protective marrow niches. Heparin disrupts CXCL12-mediated sequestration of cells in the marrow. CX-01 is a low-anticoagulant heparin derivative. In this pilot study, we combined CX-01 with chemotherapy for the treatment of AML. Induction consisted of cytarabine and idarubicin (7 + 3) with CX-01. Twelve patients were enrolled (median age, 56 years; 3 women). Three, 5, and 4 patients had good-, intermediate-, and poor-risk disease, respectively. Day 14 bone marrows were available on 11 patients and were aplastic in all without detectable leukemia. Eleven patients (92%) had morphologic complete remission after 1 induction (CR1). Eight patients were alive at a median follow-up of 24 months (4 patients in CR1). Three patients received an allogeneic stem cell transplant in CR1. Median disease-free survival was 14.8 months. Median overall survival was not attained at the maximum follow-up time of 29.4 months. No CX-01-associated serious adverse events occurred. Median day to an untransfused platelet count of at least 20×10<sup>9</sup>/L was 21. CX-01 is well tolerated when combined with intensive therapy for AML and appears associated with enhanced count recovery and treatment efficacy.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 381-389 (9 pages)Journal (Volume, Issue Number)
Blood Advances (Volume 2, Issue 4)Publication milestones
- Published - 02/27/2018
Publication status
Published - 02/27/2018
ISSN
2473-9529Publication IDs
- Scopus: 85056610351
- PubMed: 29467192
Publication metrics
Metrics
SciVal
FWCI
1.55
SciVal
Author count
15
SciVal
citations
19
SciVal
Paper percentile
91
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.07
Fractional count
14
Fractional count
0.93
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
55
Citation count
54
Mentions
22
Funding Details
FunderFunding number
NCI
R01CA178397
